Data from Immunophotonics Phase 1b/2a Clinical Trial to Be Presented at ASCO 2026
By activating systemic adaptive immunity, IP 001 may enable immune effector cells to identify and eliminate tumor cells throughout the body. SAINT LOUIS, MO, UNITED STATES, May 19, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical- …